KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Assets Average (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Assets Average for 8 consecutive years, with $485.2 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Assets Average fell 1.46% year-over-year to $485.2 million, compared with a TTM value of $485.2 million through Mar 2025, down 1.46%, and an annual FY2024 reading of $503.7 million, changed N/A over the prior year.
  • Assets Average was $485.2 million for Q1 2025 at Biocryst Pharmaceuticals, down from $490.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $526.4 million in Q3 2023 and bottomed at $324.3 million in Q1 2023.
  • Average Assets Average over 3 years is $479.0 million, with a median of $490.8 million recorded in 2024.
  • Peak annual rise in Assets Average hit 51.82% in 2024, while the deepest fall reached 9.55% in 2024.
  • Year by year, Assets Average stood at $519.9 million in 2023, then decreased by 5.6% to $490.8 million in 2024, then decreased by 1.14% to $485.2 million in 2025.
  • Business Quant data shows Assets Average for BCRX at $485.2 million in Q1 2025, $490.8 million in Q4 2024, and $481.8 million in Q3 2024.